Product Description
AbbVie is developing ABBV-3067 as a treatment for cystic fibrosis. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03969888)
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05538585 |
M23-492 FE | P1 |
Completed |
Cystic Fibrosis |
2022-12-21 |
23% |
2023-01-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03969888 |
M19-530 | P2 |
Completed |
Cystic Fibrosis |
2022-06-09 |
72% |
2023-06-30 |
Primary Endpoints |
2019-000750-63 |
2019-000750-63 | P2 |
Unknown status |
Cystic Fibrosis |
2021-07-31 |
72% |
2022-03-13 |
Treatments |
2020-005805-25 |
2020-005805-25 | P2 |
Completed |
Cystic Fibrosis |
None |
69% |
2025-07-07 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/16/2024 |
News Article |
Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie |
|
08/03/2022 |
News Article |
Global Cystic Fibrosis Market Report 2022-2030 - Expanding Therapeutic Options is Expected to Drive Market Growth |